Anti-Synthetase Syndrome
Neurology
Prevalence
5.0 / 100K
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| rese-cel | Cabaletta Bio, Inc. (CABA) |
Phase 1(1)
Compare drugs
Frequently asked questions
How many drugs are in development for Anti-Synthetase Syndrome?
BioSniper tracks 2 drugs in development for Anti-Synthetase Syndrome across 1 company.
How many clinical trials target Anti-Synthetase Syndrome?
There are 1 clinical trial targeting Anti-Synthetase Syndrome tracked by BioSniper.
What is the prevalence of Anti-Synthetase Syndrome?
The estimated prevalence of Anti-Synthetase Syndrome is approximately 5.0 per 100,000 population.
Deep-dive into Anti-Synthetase Syndrome
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis